BPC 157 Explained: Benefits, Safety & Oral vs Injectable Options BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with OncLive's FDA Approval Report: The Regulatory Rundown for March 2025 OncLive Current Landscape of FDA Stem Cell Approvals and Trials 2023 2025 Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea